RecruitingNon-obstructive Hypertrophic Cardiomyopathy
A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
Eligible age
18+ yrs
Accepts
All genders
Locations
15 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
FORTITUDE-HCM is a global, multicenter, double-blind, parallel-group, placebo-controlled Phase 2b study that will assess the efficacy and safety of ninerafaxstat compared to placebo on top of Standard of Care in patients with symptomatic nHCM
Sponsor: Imbria Pharmaceuticals, Inc.
Where it's recruiting
California
La Jolla · Los Angeles · San Francisco
District of Columbia
Washington D.C.
Florida
Miami
Illinois
Chicago · Oak Lawn
Maryland
Baltimore
Massachusetts
Boston · Burlington
Michigan
Grand Rapids
Minnesota
Rochester
Missouri
St Louis
New York
New York
North Carolina
Charlotte
Oregon
Portland
Source: ClinicalTrials.gov · NCT07023614 · last updated 2026-05-18